Alliance to Cure Cavernous Malformation Recognizes Beth Israel Deaconess Medical Center as a CCM Clinical Center

Beth Israel Deaconess Medical Center has been recognized as a designated Clinical Center by the Alliance to Cure Cavernous Malformation for the treatment of cavernous malformations.

A cavernous malformation, also known as a cerebral cavernous angioma or cavernoma, is a mulberry-shaped collection of abnormal blood vessels with thin, leaky walls, most often found in the brain and the spinal cord. They can develop and hemorrhage at any age, including in young children, though they are most likely to become symptomatic when a person is between ages 20-40.

Beth Israel Deaconess Medical Center (BIDMC) in Boston, Massachusetts, is a comprehensive healthcare facility dedicated to providing specialized care for a broad spectrum of patients. Under the leadership of Dr Ogilvy, BIDMC provides leading-edge endovascular/surgical treatment for patients with brain aneurysms, cavernous malformations, and other brain and spine vascular problems. They are dedicated to providing comprehensive, well-coordinated, and compassionate care. Their multidisciplinary team of specialists works closely together to create a customized care plan for every patient, giving patients the broadest range of treatment alternatives, including less invasive options when appropriate. They share an innate desire to help people with complex vascular problems of the brain/spinal cord by using surgical skills. They are involved in innovative trials that provide the ability to offer the latest treatments as they evolve.

Christopher S. Ogilvy, MD, is a cerebrovascular neurosurgeon at Beth Israel Deaconess Medical Center and a professor of neurosurgery at Harvard Medical School.  Dr. Ogilvy also serves as the Medical Director of their new Cerebral Cavernous Malformation (CCM) Clinical Center.  Dr. Ogilvy is known nationally and internationally for his work in neurointerventional and operative procedures and has been a moving force in the field of neurovascular disease for the last thirty years.

Dr. Ogilvy’s research and academic endeavors are in the areas of neurovascular disease including intracranial aneurysms, arteriovenous malformations, and atherosclerotic disease.  Much of his work has been focused on studying outcomes of operative and endovascular procedures. In the laboratory, efforts have been focused on studying cerebral ischemia in the setting of neurovascular procedures, with a recent focus on the biology of intracranial aneurysms and the role of endothelial cells in the treatment of intracranial aneurysms. He has pioneered several techniques in surgical procedures and is pursuing avenues of research in clinical treatment of patients with intracranial vascular problems using endovascular techniques.

Dr. Ogilvy has served on numerous national neurosurgical committees.  He is the Medical Director of the Brain Aneurysm Foundation, a national organization to help patients and families with brain aneurysms and to fund clinical and basic research. He has published extensively, with over 400 original manuscripts and over 125 book chapters in the area of neurovascular surgery.

Dr. Philipp Taussky is a neurological surgeon at Beth Israel Deaconess Medical Center and has extensive experience in neurocritical care disorders.  Dr. Taussky serves as Co-Director of their CCM Clinical Center.  He served the Department of Neurosurgery at the University of Utah as the Section Chief of Neurovascular Surgery and Chief Value Officer. He earned his MD degree at the University of Basel. He completed a skull base/cerebrovascular fellowship at the University of Utah and an endovascular fellowship at the Mayo Clinic, focusing on minimally invasive techniques to treat stroke, aneurysms, AVMs, and other vascular diseases. Because of his dual training, he has a unique perspective, offering his patients both microsurgical and minimally invasive endovascular treatment for vascular disease.  Dr. Taussky has published over 120 papers and book chapters and has lectured both nationally and internationally. He provides consultation and management for patients with AVMs, aneurysms, cavernous malformations, meningiomas, Moya-Moya, stroke, carotid disease, and other cerebral problems.

“We welcome Beth Israel Deaconess into our growing network of recognized CCM Clinical Centers. We are pleased to recognize the expert, multidisciplinary care Dr. Ogilvy, Dr. Taussky, and their team offer our patients,”, said Connie Lee, PsyD, chief executive officer of The Alliance to Cure Cavernous Malformation.  “Cerebral cavernous malformations are not rare but infrequently diagnosed, which makes finding knowledgeable care challenging. The greater Boston area is fortunate to have Beth Israel Deaconess to serve our adult CCM patients.

The designated, multidisciplinary team at Beth Israel Deaconess Medical Center includes:

  • Christopher S. Ogilvy, MD, Director and Neurosurgeon
  • Philipp Taussky, MD, Co-Director and Neurosurgeon
  • Magdy H. Selim, MD, PhD, Neurologist
  • Sandeep Kumar, MD, Vascular Neurologist
  • Jennifer L. Dearborn-Tomazos, MD, Vascular Neurologist
  • Bernard Chang, MD, Epileptologist
  • Srivastava Siddharth, MD, Geneticist (at Boston Children’s)
  • David B. Hackney, MD, Neuroradiologist
  • Deidre Buckley, RN, Nurse Practitioner

The Alliance to Cure Cavernous Malformation is a patient research organization dedicated to informing, supporting, and mobilizing those impacted by CCMs and driving research for better treatments and a cure.  Beth Israel Deaconess Medical Center is required to meet specific criteria to achieve CCM Clinical Center status including, but not limited to:

  • Designating a medical director or co-directors
  • Designating multidisciplinary board-certified specialists, including a cerebrovascular neurosurgeon; a neurologist with cerebrovascular specialization or pediatric neurologist; an epileptologist; a neuroradiologist; a nurse coordinator; and a geneticist who all collaborate for the diagnosis and management of patients with CCM
  • Meeting or exceeding all consensus guidelines approved by the Scientific Advisory Board
  • Establishing a single point of entry, allowing all appointments to be scheduled with one call
  • Providing coordinated appointments for patients over no more than two days, reducing the travel burden on out-of-town patients
  • The complete list of criteria for a CCM Clinical Center is available on the Alliance to Cure website.

Updated 05/20/23